Introduction: Ketosis is a metabolic state associated with insulin deficiency. Untreated, it develops into diabetic ketoacidosis, a significant contributor to mortality and morbidity in people with type 1 diabetes mellitus (T1DM). Little is understood about how patients utilize healthcare resources during ketosis events. This study aimed to identify and quantify healthcare resource utilization and provide estimates of associated costs of ketosis events in T1DM, treated unaided or with healthcare professional (HCP) assistance in the UK.
Methods: Qualitative interviews with adult patients, pediatric carers, and HCPs identified resources used by patients/carers during ketosis events. An online quantitative survey was then used to quantify patients/carers resource use during their/their child's most recent ketosis event, and HCPs estimated patient resource uptake to corroborate the findings. Associated costs estimated from UK data sources were applied to the survey results to calculate the cost of ketosis events in adults and children.
Results: Quantitative survey responses from 93 adults, 76 carers, and 52 HCPs were analyzed. Patients and carers monitored ketosis during and following the event with ketone strips and additional glucose strips, and administered treatment comprising insulin and pump set changes where appropriate. Additionally, patients/carers accessed phone services and many received follow-up medical appointments. In total, 70% (n = 65) of adult and 66% (n = 50) of pediatric ketosis events were managed at home, for which resource use costs per event were £23.87 and £38.00 respectively. Remaining events were treated in NHS facilities costing £217.57 per adult and £352.92 per child. Weighted averages identified that ketosis events cost £81.98 per adult and £142.97 per child. Indirect costs from work productivity loss increase these figures to £225.11 per adult and £256.88 per child.
Conclusions: Healthcare resource use for ketosis events is high in adults and children with T1DM and imposes an underappreciated economic burden for the NHS.
Funding: Novo Nordisk A/S.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630560 | PMC |
| http://dx.doi.org/10.1007/s13300-017-0305-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- * She was diagnosed with hyperglycemia and ketosis, treated for diabetic ketoacidosis (DKA) with insulin, and later transitioned to an insulin regimen after discharge.
- * The case is significant for recognizing immune checkpoint inhibitor-induced diabetes mellitus (ICI-DM) as a potential side effect of immunotherapy, leading to the discontinuation of her cancer treatment and planning for surgery.
Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.
BMC Med
December 2024
Biology Department, Boston College, Chestnut Hill, MA, 02467, USA.
Article Synopsis
- Glioblastoma (GBM) is the deadliest brain tumor in adults, and current therapies are largely ineffective, which drives the need for new treatment strategies based on the tumor's metabolic needs, specifically glucose and glutamine.
- A ketogenic metabolic therapy (KMT) approach targets these metabolic pathways by combining dietary changes with specific drugs to limit glycolysis and glutaminolysis, while promoting the use of non-fermentable fuels like ketones and fatty acids.
- The glucose-ketone index (GKI) serves as a biomarker to monitor treatment effectiveness, aiming to create a more hostile environment for tumor growth and improve outcomes in GBM as well as potentially other cancer types reliant on similar metabolic pathways.
Adverse event reporting of combining SGLT2 inhibitor and GLP1 receptor agonist: A real-world study from FAERS.
Nutr Metab Cardiovasc Dis
January 2025
Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address:
Background And Aims: We evaluate whether the combination of sodium-glucose cotransporter-2 inhibitor(SGLT2i) and glucagon-like peptide-1 receptor agonist(GLP1RA) disproportionally increases the reporting of adverse events compared with SGLT2i or GLP1RA monotherapy in the FDA adverse event reporting system (FAERS).
Methods And Results: Adverse events related to SGLT2i and GLP1RA were screened and selected, then data from the FAERS was underwent thorough disproportionality analysis. The proportional reporting ratio(PRR) of SGLT2i-related adverse events were compared between patients using SGLT2i alone and those using both SGLT2i and GLP1RA.
The peri-operative implications of sodium-glucose co-transporter 2 inhibitors: a narrative review.
Anaesthesia
January 2025
Department of Anaesthesiology, University of Hong Kong, Hong Kong.
Introduction: Sodium-glucose co-transporter 2 inhibitors are a novel class of antihyperglycaemic drugs used in the management of type 2 diabetes, that improve glycaemic control, cardiovascular outcomes and promote weight loss. They are also approved for the treatment of heart failure and chronic kidney disease in patients with or without diabetes. This narrative review discusses the peri-operative effects and implications of sodium-glucose co-transporter 2 inhibitors and gives an overview of current evidence and existing peri-operative guidelines.
View Article and Find Full Text PDFClinical features and outcomes of patients diagnosed with diabetic ketoacidosis (DKA) who were hospitalized for conditions outside of internal medicine.
J Diabetes Complications
December 2024
Department of Internal Medicine F, Soroka University Medical Center, Beer-Sheva, Israel.
Article Synopsis
- - The study examined clinical features and outcomes of patients admitted for diabetic ketoacidosis (DKA) outside of internal medicine from 2005 to 2022, focusing on differences between internal and non-internal medicine cases.
- - Among 429 patients, those outside of internal medicine were generally older and had higher rates of diabetes complications, with poorer outcomes such as lower glucose levels and increased need for mechanical ventilation.
- - The findings suggest that patients admitted for surgical or obstetrical conditions are at a higher risk for severe DKA complications, necessitating further research to understand these unique patient characteristics better.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!